RetiNova Therapeutics

Executive Summary

RetiNova Therapeutics is a preclinical-stage biotechnology company developing Noregen™ (CTR-107), a synthetic norrin mimic designed to reverse vision loss by restoring retinal vascular health. The lead candidate targets ischemic retinal diseases, including diabetic macular edema (DME) and retinal vein occlusion (RVO), which affect millions worldwide and represent significant unmet medical needs. Unlike current therapies that primarily manage symptoms, Noregen aims to address the underlying ischemia by stabilizing the blood-retinal barrier and promoting vascular repair. Preclinical studies have demonstrated promising efficacy in animal models, showing improved retinal function and reduced edema. The company is based in Cambridge, Massachusetts, and is advancing Noregen toward clinical development with a focus on DME as the initial indication. As a private company in the early stages of drug development, RetiNova faces typical risks related to regulatory approval, clinical trial outcomes, and financing. However, the unique mechanism of action and potential to modify disease progression differentiate Noregen from existing anti-VEGF therapies. The company's near-term focus is on completing IND-enabling studies and securing partnerships or funding to support a first-in-human trial. If successful, RetiNova could offer a paradigm-shifting treatment for retinal diseases, but significant execution hurdles remain before reaching commercialization.

Upcoming Catalysts (preview)

• Q4 2026IND Filing for Noregen (CTR-107) in DME60% success
• Q1 2027Initiation of Phase 1 Clinical Trial50% success
• Q3 2026Series A Financing or Strategic Partnership40% success